Cancer-Fighting Chemical Found in Human Skin Bacteria

A molecule produced by a strain of Staphylococcus epidermis interferes with DNA synthesis.

Mar 1, 2018
Diana Kwon

S. epidermidis growing on an agar plateGALLO AND NAKATSUJI, DERMATOLOGY, UC SAN DIEGO

A strain of Staphylococcus epidermis found on human skin contains a chemical with cancer-fighting abilities, according to a study published yesterday (February 28) in Science Advances

“The presence of this strain may provide natural protection, or it might be used therapeutically to inhibit the growth of various forms of cancer,” Richard Gallo, a physician-scientist at the University of California, San Diego, tells The Guardian.

While Gallo and his colleagues were examining the antimicrobial properties of skin bacteria, they came across a strain of S. epidermis that produced 6-N-hydroxyaminopurine (6-HAP), a molecule that resembles adenine, a key constituent of DNA. “Because of that structure, we wondered if it interfered with DNA synthesis,” Gallo tells Science News.

When the team investigated further, they found that 6-HAP blocked the activity of DNA polymerase, an enzyme required for the formation of DNA. They also discovered that 6-HAP was able to inhibit the proliferation of various types of tumor cells, such as melanoma and lymphoma, in a dish. The chemical did not inhibit the growth of normal human skin cells, because they possess 6-HAP-deactivating enzymes that were not present on cancerous cells. 

The researchers then applied the 6-HAP-producing bacteria to mice’s skin and found that the animals developed fewer premalignant skin tumors after being irradiated with UV light than rodents that received a strain of the microbes that didn’t produce the chemical.

The findings highlight “the potential of the microbiome to influence human disease,” Lindsay Kalan, a biochemist at the University of Wisconsin–Madison, tells Science News. However, she adds, “it is important to understand how the microbiome interacts with its human host before we can begin to manipulate it for disease treatment.”

November 2018

Intelligent Science

Wrapping our heads around human smarts


Sponsored Product Updates

Improved Accuracy in Multiplex Assays

Improved Accuracy in Multiplex Assays

Interference by endogenous antibodies in immunoassays is a well-documented phenomenon. Download this poster to learn about the profound effects that this can have on the data and how development expertise and assay design can eliminate or reduce the effects of endogenous antibodies.

Complete Pathology Solutions: Make Every Minute Count

Complete Pathology Solutions: Make Every Minute Count

From sample collection and handling, to fixation and processing, tissue staining, and covering all your IHC and water purification needs—you can have confidence in the quality of your results with MilliporeSigma's one-stop pathology solution.

Preparing Cell Or Tissue Lysates For ELISA Kits

Preparing Cell Or Tissue Lysates For ELISA Kits

RayBiotech manufactures over 2,000 high fully validated, GMP-compliant ELISA kits. In this blog post we explain how to prepare cell or tissue lysates for ELISA Kits.

Norgen Biotek Achieves Illumina Propel Certification as a Service Provider for Next Generation Sequencing

Norgen Biotek Achieves Illumina Propel Certification as a Service Provider for Next Generation Sequencing

Norgen Biotek Corp., an innovative privately held Canadian biotechnology company focusing primarily on nucleic acid and protein stabilization and purification, as well as providing high quality services to the scientific community, today announced that it has become Propel-Certified through Illumina as a Next Generation Sequencing (NGS) service provider.